Companies House true 2025-01-01 2025-12-31 false 15365053 uk-bus:Director1 2025-01-01 2025-12-31 15365053 uk-bus:Director2 2025-01-01 2025-12-31 15365053 2025-01-01 2025-12-31 15365053 2025-12-31 15365053 uk-bus:EntityHasNeverTraded 2025-01-01 2025-12-31 15365053 uk-bus:FRS102 2025-01-01 2025-12-31 15365053 uk-bus:FullAccounts 2025-01-01 2025-12-31 15365053 uk-bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 15365053 2024-12-31 15365053 uk-bus:OrdinaryShareClass1 2025-01-01 2025-12-31 15365053 uk-bus:OrdinaryShareClass2 2025-01-01 2025-12-31 15365053 uk-bus:OrdinaryShareClass3 2025-01-01 2025-12-31 15365053 uk-bus:PreferenceShareClass1 2025-01-01 2025-12-31 15365053 uk-bus:PreferenceShareClass2 2025-01-01 2025-12-31 15365053 uk-bus:PreferenceShareClass3 2025-01-01 2025-12-31 15365053 uk-core:ShareCapitalPreferenceShares 2025-12-31 15365053 uk-core:ShareCapitalPreferenceShares 2024-12-31 iso4217:GBP iso4217:GBP xbrli:shares xbrli:shares

Registered Number 15365053

GINGER SCIENCE & PHARMACEUTICAL LTD

Dormant Accounts

31 December 2025

GINGER SCIENCE & PHARMACEUTICAL LTD Registered Number 15365053

Balance Sheet as at 31 December 2025

2025 2024
£ £
Current assets
Cash at bank and in hand
100
100
Net assets
100
100
Issued share capital
50 A Ordinary Shares of £ 1 each 50 50
50 B Ordinary Shares of £ 1 each 50 50
Total Shareholder funds
100
100

STATEMENTS

  1. For the year ending 31 December 2025 the company was entitled to exemption under section 480 of the Companies Act 2006 relating to dormant companies.
  2. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
  3. The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
  4. These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Approved by the Board on 14 September 2026

And signed on their behalf by:
Timothy Byrne, Director